The purpose of the COST Action CA19114 entitled “Network for Optimized Astatine-labeled Radiopharmaceuticals” (NOAR) is to create a network of scientists to investigate the production conditions of the α-particle emitter Astatine-211 (Astatine-211: ²¹¹At) and its application in Targeted Alpha Therapy (TAT) of cancer. This COST Action brings together experts from more than 20 countries, who will be involved in the production, radiochemistry, biology and preclinical evaluation of ²¹¹At radiopharmaceuticals, as well as in their clinical application.